Active and passive Aβ-immunotherapy: Preclinical and clinical studies and future directions: Part II

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 2, 2009, Pages 82-87

  Cribbs, David H ^a   Agadjanyan, Michael G ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTE FOR MOLECULAR MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACC 001; AD 01; AD 02; ALUMINUM POTASSIUM SULFATE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; BAPINEUZUMAB; CAD 106; EPITOPE; GSK 933776A; HUMAN IMMUNOGLOBULIN; LY 2062430; MONOCLONAL ANTIBODY; NEUROTOXIN; PF 04360365; PF 4360365; PLACEBO; QS 21; R 1450; UNCLASSIFIED DRUG; V 950; ANTIBODY;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; AORTA STENOSIS; ASEPTIC MENINGITIS; ASTROCYTOSIS; AUTOPSY; BINDING AFFINITY; BLEEDING; BRAIN HEMORRHAGE; CELL ACTIVATION; CLINICAL STUDY; CLINICAL TRIAL; DISEASE COURSE; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EARLY INTERVENTION; EDEMA; EDITORIAL; ENCEPHALITIS; HEALTH CARE COST; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMMUNE RESPONSE; INFLAMMATION; INJURY; MENINGOENCEPHALITIS; MICROANGIOPATHY; MICROGLIA; NEUROPATHOLOGY; NEUROPATHY; NONHUMAN; PASSIVE IMMUNIZATION; RISK BENEFIT ANALYSIS; SENILE PLAQUE; THORAX PAIN; VASCULAR AMYLOIDOSIS; ANIMAL; BRAIN; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; STATISTICS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; BRAIN; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE;

EID: 67649660323     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709787847270     Document Type: Editorial

References (28)

1. www.alzforum.org. Alzheimer Research Forum, 2009.
2. Paulson, H.L. Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold. Am. J. Hum. Genet., 1999, 64, 339-45.
3. Walker, L.C.; Levine, H., 3rd; Mattson, M.P.; Jucker, M. Inducible proteopathies. Trends Neurosci., 2006, 29, 438-43.
4. Schenk, D. Current challenges for the successful treatment and prevention of Alzheimer's disease: treating the pathologies of the disease to change its clinical course. Alzheimers Dement., 2008, 4, S119-21.
5. Hardy, J. Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297, 353-6.
6. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [see comments]. Nature, 1999, 400, 173-7.
7. Janus, C.; Pearson, J.; McLaurin, J.; Mathews, P.M.; Jiang, Y.; Schmidt, S.D.; Chishti, M.A.; Horne, P.; Heslin, D.; French, J.; Mount, H.T.; Nixon, R.A.; Mercken, M.; Bergeron, C.; Fraser, P.E.; St George-Hyslop, P.; Westaway, D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 2000, 408, 979-82.
8. Morgan, D.; Diamond, D.M.; Gottschall, P.E.; Ugen, K.E.; Dickey, C.; Hardy, J.; Duff, K.; Jantzen, P.; DiCarlo, G.; Wilcock, D.; Connor, K.; Hatcher, J.; Hope, C.; Gordon, M.Arendash, G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408, 982-5.
9. Bard, F.; Cannon, C.; Barbour, R.; Burke, R.L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F.; Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.Yednock, T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 2000, 6, 916-9.
10. DeMattos, R.B.; Bales, K.R.; Cummins, D.J.; Dodart, J.C.; Paul, S.M.; Holtzman, D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2001, 98, 8850-5.
11. Dorshkind, K.; Montecino-Rodriguez, E.; Signer, R.A. The ageing immune system: is it ever too old to become young again? Nat. Rev. Immunol., 2009, 9, 57-62.
12. Pawelec, G. Immunosenescence comes of age. Symposium on Aging Research in Immunology: the Impact of Genomics. EMBO Rep., 2007, 8, 220-3.
13. Fiala, M.; Cribbs, D.H.; Rosenthal, M.; Bernard, G. Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. J. Alzheimers Dis., 2007, 11, 457-63.
14. Solomon, B.; Koppel, R.; Frankel, D.; Hanan-Aharon, E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA, 1997, 94, 4109-12.
15. Mamikonyan, G.; Necula, M.; Mkrtichyan, M.; Ghochikyan, A.; Petrushina, I.; Movsesyan, N.; Mina, E.; Kiyatkin, A.; Glabe, C.; Cribbs, D.H.; Agadjanyan, M.G. Anti-Abeta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils, but not the most toxic oligomers. J. Biol. Chem., 2007, 282, 22376-86.
16. Greenberg, S.M.; Vernooij, M.W.; Cordonnier, C.; Viswanathan, A.; Al-Shahi Salman, R.; Warach, S.; Launer, L.J.; Van Buchem, M.A.; Breteler, M.M. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol., 2009, 8, 165-74.
17. Boche, D.; Nicoll, J.A. The role of the immune system in clearance of abeta from the brain. Brain Pathol., 2008, 18, 267-78.
18. Hawkes, C.A.; McLaurin, J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc. Natl. Acad. Sci. USA, 2009, 106, 1261-6.
19. Nicoll, J.A.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H.; Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med., 2003, 1, 448-52.
20. Masliah, E.; Hansen, L.; Adame, A.; Crews, L.; Bard, F.; Lee, C.; Seubert, P.; Games, D.; Kirby, L.; Schenk, D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology, 2005, 64, 129-31.
21. Gilman, S.; Koller, M.; Black, R.S.; Jenkins, L.; Griffith, S.G.; Fox, N.C.; Eisner, L.; Kirby, L.; Rovira, M.B.; Forette, F.Orgogozo, J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005, 64, 1553-62.
22. Pride, M.; Seubert, P.; Grundman, M.; Hagen, M.; Eldridge, J.; Black, R.S. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener. Dis., 2008, 5, 194-6.
23. Trouche, S.G.; Asuni, A.; Rouland, S.; Wisniewski, T.; Frangione, B.; Verdier, J.M.; Sigurdsson, E.M.; Mestre-Frances, N. Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives. Vaccine, 2009, 27, 957-64.
24. Jennings, G.T.; Bachmann, M.F. The coming of age of virus-like particle vaccines. Biol. Chem., 2008, 389, 521-36.
25. Winblad, B. Safety, tolerability and immunogenicity of the Ab immunotherapeutic vaccine CAD 106 in a first-in-man study in Alzheimer patients. International Conference on Alzheimer's Disease (ICAD), 2008, Abstract S2-04-06.
26. Grundman, M.A.B.R. Clinical trials of bapineuzumab a beta-amyloid-targeted immunotherapy in patients with mild-to-moderate Alzheimer's disease. Int. Conference Alzheimer's Dis., (ICAD), 2008, Abstract O3-04-05.
27. Relkin, N.R.; Szabo, P.; Adamiak, B.; Burgut, T.; Monthe, C.; Lent, R.W.; Younkin, S.; Younkin, L.; Schiff, R.; Weksler, M.E. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging, 2008.
28. Siemers, E.R. Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease. Int. Conference Alzheimer's Dis. (ICAD) Chicago, 2008, Abstract P4-346.